Foot and Ankle Devices Market: Zimmer Biomet Makes $1.2B Move

The medtech industry is off to a fast start in 2025, with Zimmer Biomet making a major acquisition that is set to reshape its position in the foot and ankle devices market. This week, the orthopedic giant announced its decision to acquire Paragon 28 for $1.2 billion, marking a significant shift in Zimmer Biomet’s strategic focus.

In this blog, we’ll break down how this deal strengthens Zimmer Biomet’s foothold in the foot and ankle space, examine the growing potential of the foot and ankle devices market, and explore the numbers highlighting why this market is becoming increasingly important for companies like Zimmer Biomet.

A Strong Move in Foot and Ankle Devices

Founded in 2010, Paragon 28 has positioned itself as a leader in the foot and ankle space, focusing on developing and commercializing surgical implants for various foot and ankle conditions. This includes addressing deformities, fractures, joint replacements, and trauma. Paragon 28’s business model is built around a portfolio of specialized products aimed at treating complex issues in this part of the body, which has become an increasingly vital niche within the broader orthopedic space.

Between 2022 and 2023, Paragon 28 reported impressive growth, with revenue jumping by 19%, totaling $216.4 million. Their success is clearly reflected in their year-over-year revenue, and this growth trajectory made Paragon 28 an attractive target for Zimmer Biomet.

Zimmer Biomet’s CEO, Ivan Tornos, commented on the acquisition, noting that it would enhance its position in one of the highest-growth specialized segments within musculoskeletal care. This acquisition is expected to not only consolidate Zimmer Biomet’s presence in the foot and ankle market but also create new opportunities in ambulatory surgery centers (ASCs), a rapidly growing space in healthcare.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/foot-and-ankle-devices-market-zimmer-biomet-makes-12b-move 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more